Kornimate/medical-research-clean huggingface dataset:
study of low dose ct in sarcoma patients

Conditions: Soft Tissue Sarcoma

Summary: the primary outcome of this study is the detection of lung metastases comparing low dose ct (ldct) and minimum dose ct (mndct) with cxr. hypothesis 1. ldct and mndct have similar sensitivity for the detection of lung nodules (metastases). 2. mndct of the thorax detects a larger number of nodules (metastases) than cxr.

a 3-year prospective phase ii non-randomized study commenced may 2003 enrolling 60 high-risk patients with intermediate and high grade sts. each patient is kept under radiological surveillance for 3 years unless lung metastases are detected. conventional thoracic imaging for staging and surveillance of sts patients is shown in figure 1. in the trial, ldct and mndct are added to each imaging visit (figure 1). a 2-view cxr (cr) is performed (direct view, kodak, rochester) followed by thoracic ct scans performed on a siemens 16 row mdct (sensation 16, siemens, erlangen), ct acquisition; 120kvp, 5/2.5/2.5mm. images are reconstructed with high and low spatial frequency filters and soft copy viewing is performed on a standalone pacs workstation using standard mediastinal (w 350, l 40) and lung (w 1500, l -600) settings. examinations are performed with varying mas; sdct 120 mas, ldct 40 mas and mndct 20 mas. the examinations are evaluated, blinded to the results of the alternative and previous studies, for the presence of nodules (defined as a non-calcified focal opacity ≥3 mm \< 3 cm). surveillance imaging is commenced 3 months post surgery.

Eligibility criteria:
inclusion criteria: * high grade soft tissue sarcoma exclusion criteria: * none
motor rehabilitation technologies for children with disability: a cross-european survey

Conditions: Children With Disabilities; Motor Rehabilitation; Technologies

Summary: the aim of the rehatech4child survey led by eacd is to identify the digital technologies (e.g., robotic devices and treadmill systems, virtual reality and gaming systems, telehealth) that are used in clinical practices throughout europe, and to know more about how rehabilitation professionals use or not use digital technologies in motor rehabilitation practices within the paediatric population. this knowledge would eventually help in designing the future technological developments based on the feedback from rehabilitation professionals.


Eligibility criteria:
inclusion criteria: * rehabilitation professionals who use or not technologies in pediatric motor rehabilitation * practice in europe exclusion criteria: -
meru health program for cancer patients with depression and anxiety

Conditions: Depression; Anxiety

Summary: the primary objective of this study is to evaluate clinical outcomes among people with cancer who participate in a 12-week therapist-supported digital mental health intervention (dmhi) called the meru health program (mhp). study participants (n=20) will be referred to the mhp through the cancer support community (csc) helpline and network of gilda's club locations. the main outcomes will be depression symptoms, anxiety symptoms, health-related quality of life (hrqol), intervention adherence, and intervention satisfaction. the secondary objective will be to determine the acceptability of the screening and referral process from the csc networks into the mhp. data pertaining to implementability will be collected from study participants, mhp clinicians, and csc staff.

the goal of this single-arm intervention study is to test the feasibility of the meru health program (mhp) in reducing symptoms of depression and anxiety among 20 people with cancer referred from the cancer support community (csc). the mhp is a 12-week digital mental health intervention delivered via a smartphone app. the intervention focuses on cognitive behavioral techniques and mindfulness skills with the aim of improving mental health symptoms. the platform provides informational videos, skills practices, group discussion, and messaging with a licensed clinician employed by meru health. the licensed clinician supports patients as needed and reviews engagement logs within the app. as part of the intervention, depression and anxiety symptoms are measured on a biweekly basis over 12 weeks. for this study, self-reported surveys will be administered at baseline, week 12, and 2-months post-treatment to measure health-related quality of life and intervention satisfaction. in-depth interviews will be conducted with patients. two focus groups will be conducted with mhp clinicians and csc navigators to understand barriers and facilitators to the screening processes and intervention delivery.

Eligibility criteria:
inclusion criteria: * positive screen (score \>= 3 out of 8) on the anxiety or depression subscale of the css 15+ questionnaire * phq-9 and/or gad-7 score \>= 5 at clinical intake * willing to commit to the meru health program if selected * proficient in the english language * at least 18 years of age at the time of enrollment * has a valid mailing address * owns 1 of the 3 past versions of an apple or android mobile phone operating system * currently in active cancer treatment at the time of enrollment exclusion criteria: * active suicide intent with plan to act * substance use disorder in the past 3 months * lifetime bipolar disorder * lifetime psychotic disorder * currently pregnant * less than 3 months postpartum

Keywords: mental health digital mental health depression anxiety meru health
ultrasound guided radiofrequency ablation of the occipital nerve

Conditions: Nerve Pain

Summary: study an ultrasound guided approach to radiofrequency ablation of the occipital nerve that makes it possible to see the needle during treatment procedure. it is hoped this will reduce the amount of pain after the standard of care procedure.


Eligibility criteria:
inclusion criteria: * patients between the ages of 18-80 with a diagnosis of occipital neuralgia or migraine overlying the occipital region. * a diagnosis of occipital neuralgia will be based on the international classification of headache disorders (ichd), whose criteria include: paroxysmal stabbing pain in the distribution of the gon, tenderness over the affected nerve, and relief of pain for at least 3 hours after bupivacaine local anesthetic block of the affected nerve. * patients may also be included if they have a diagnosis of migraine based on the ichd criteria with predominance of pain over the occipital region that responded to occipital nerve block. * patients must have failed oral medications including nsaids, opioids, and anticonvulsants for the management of their pain. * failed treatment will be \<50% pain reduction with oral medication. * patients must report headache frequency of at least 10 days per month. exclusion criteria: * patients will be excluded from the trial if they have an unstable medical or psychological condition, * are pregnant, * have an implanted cardiac pacemaker or defibrillator that could not be disabled, * have had a craniotomy or scar tissue overlying the site from a previous surgery, * have a history of cervical spine fusion, * have evidence of elevated icp or intracranial tumor, * or have previous rfa treatment of the greater or lesser occipital nerve.
comparison of solid organ transplant

Conditions: Gram-Negative Bacterial Infections; Gram-negative Bacteremia; Multidrug-Resistant Organism; Hospital-acquired Pneumonia; Healthcare-associated Pneumonia

Summary: solid organ transplant (sot) recipients have increased incidence of infections with mdro pathogens. this difference leads to a disparity in antibiograms between sot recipients and other hospitalized patients.

there is limited guidance for empiric antimicrobial therapy in this population. local epidemiology plays a voluble role in managing infections empirically within the hospital setting. antibiograms can serve as a critical tool in optimizing empiric antimicrobial decisions. refining antibiogram data to specific populations such as sot patients may allow for timelier and appropriate empiric use of antimicrobials, and improve clinical outcomes. time to appropriate therapy (antimicrobial testing susceptible in vitro to the pathogen identified) is of vital importance in management of serious infections. sot may have different resistance rates at methodist dallas medical center making the applicability of the yearly hospital-wide antibiogram unknown for use in this specialized patient population. a sot-specific antibiogram may highlight common resistance patterns identified in pathogens seen in this patient population. additionally, this investigation may further emphasize the importance of antimicrobial stewardship activities such as: appropriate empiric antibacterial decisions, de-escalation, and effective durations of therapy.

Eligibility criteria:
inclusion criteria: * 18 years or older exclusion criteria: * missing data necessary to determine study outcomes
nutraceutical on hyperglycemia

Conditions: Dysglycemia

Summary: the aim will be to evaluate if glicoset® 1000, a nutraceutical containing ilex paraguariensis, white mulberry and chromium picolinate, can be effective in improving glycemic status in subject with dysglycemia.

the aim will be to evaluate if glicoset® 1000, a nutraceutical containing ilex paraguariensis, white mulberry and chromium picolinate, can be effective in improving glycemic status in subject with dysglycemia. the investigators will enroll patients with impaired fasting plasma glucose (ifg) or impaired glucose tolerance (igt), not taking hypoglycemic agents (both pharmaceuticals or nutraceutical agents). patients will be randomized to take placebo or glicoset® 1000 for 3 months, in a randomized, double-blind, placebo-controlled design. glicoset® 1000 and placebo will be self-administered once a day, 1 tablet during the breakfast.

Eligibility criteria:
inclusion criteria: * patients with impaired fasting glucose (ifg) or impaired fasting glucose (igt) * patients not taking hypoglycemic agents (both pharmaceuticals or nutraceutical agents) exclusion criteria: * patients with type 1 or type 2 diabetes mellitus * patients with impaired hepatic function * patient with impaired renal function * patients with gastrointestinal disorders * patients with current or previous evidence of ischemic heart disease, heart failure, or stroke * patients with weight change of \> 3 kg during the preceding 3 months * patients with hystory of malignancy, and significant neurological or psychiatric disturbances, including alcohol or drug abuse. * patients taking (within the previous 3 months) hypoglycemic agents, laxatives, beta-agonists (other than inhalers), cyproheptadine, anti-depressants, antiserotoninergics, phenothiazines, barbiturates, oral corticosteroids, and antipsychotics * women who were pregnant or breastfeeding or of childbearing potential and not taking adequate contraceptive precautions.
implementation of a digital clinic for alcohol-associated liver disease and alcohol use disorder (dalc)

Conditions: Alcohol Use Disorder; Liver Diseases

Summary: the purpose of this study is to determine whether a multidisciplinary digital clinic will improve health outcomes, reduce costs, increase access, and improve provider satisfaction. the primary aim of this study is to improve clinical outcomes in patients with ald through the implementation of a novel digital health platform for personalized multi-disciplinary treatment of patients with ald and aud. secondary aims include improvement in provider and patient-reported outcomes including satisfaction with aud treatment.

this will be a pilot study with a pragmatic trial design wherein all hepatology providers at the mayo clinic in rochester, mn and scottsdale, az will be invited to participate in the study. consented providers will be randomized to the digital ald/aud clinic (dalc) arm or standard of care. provides randomized to standard of care arm will continue to enroll their patients with ald in the interactive care plan (icp), a nursing led program started at mayo in 2021 for longitudinal remote care of patients with compensated and decompensated cirrhosis. all patients will receive nursing education on alcohol abstinence at icp enrollment and longitudinal management of their liver disease (current state). providers randomized to the intervention arm will be able to refer their patients with ald, to the dalc in addition to standard of care. the target sample size will be 40 providers (20 providers per arm) and the investigators anticipate 150 patients with ald will be seen during the study period across both arms. the number of icp eligible patients seen versus the number of icp referred patients will be recorded for all providers. clinically relevant outcomes including hepatic decompensation, meld 3.0 score, liver chemistries, alcohol use or relapse, liver-related hospitalizations, medication compliance, and mortality will be recorded as part of current icp program, in both arms. data will be collected retrospectively from the available medical records at the end of the study period, and no research contact will be made with the patients after initial consent for those patients being offered the dalc. the study duration will be 6 months after the initial hepatology appointment. at study enrollment and completion, providers will be asked to fill out a survey regarding their satisfaction with ald/aud treatment. consented providers will be informed that they may drop out of the study at any time.

Eligibility criteria:
inclusion criteria: * provider-hepatology providers at mayo clinic rochester and scottsdale * patient-age ≥ 18 y.o. * patient-alcohol-associated liver disease exclusion criteria: * provider-providers in other divisions * patient-inability to provide consent

Keywords: alcohol liver disorder
a novel dynamic random-dot stereopsis assessment to measure the stereopsis in intermittent exotropia

Conditions: Dynamic Stereopsis in Intermittent Exotropia Patients

Summary: a novel dynamic random-dot stereopsis test that included motion + disparity (md), motion (m), and disparity (d), in which the disparity cues range from 200 to 1200 arc-seconds was used. the characteristics of preoperative dynamic stereopsis in 83 intermittent exotropia patients and its associations with clinical features were analysed, and the prognosis was followed up on the 1st day and 2nd, 6th and 12nd months postoperatively.


Eligibility criteria:
inclusion criteria: x(t) groups were as follows: 1. near and distance exodeviation angles greater than 5 prism degrees (pd) and alternate cover tests and x(t) diagnosis by an experienced doctor; 2. between 5 and 30 years old; 3. 0.0 or better best corrected visual acuity (bcva; logmar, log of the minimum angle of resolution); 4. absence of other ocular disorders or other systemic diseases. normal group were as follows: 1. between 5 and 30 years old; 2. 0.0 or better logmar bcva; 3. near and distance exodeviation angles less than 5 pd and alternate cover tests; and 4. no history of any ocular pathology or systemic disease. exclusion criteria: x(t) groups were as follows: 1. near and distance exodeviation angles less than 5 prism degrees (pd) 2. younger than 5 or older than 30 years old; 3. less than 0.0 or better best corrected visual acuity (bcva; logmar, log of the minimum angle of resolution); 4. has other ocular disorders or other systemic diseases. normal group were as follows: 1. younger than 5 or older than 30 years old; 2. less than 0.0 or better best corrected visual acuity (bcva; logmar, log of the minimum angle of resolution); 3. near and distance exodeviation angles more than 5 pd and alternate cover tests; 4. has history of any ocular pathology or systemic disease.
horner's sd after thoracic epidural block

Conditions: Horner's Syndrome

Summary: this study prospectively evaluates the incidence of horner's syndrome after thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy. the incidence was 1.36% and the mechanism of horner's syndrome was cephalic spread of the local anesthetic.

transient horner's syndrome has been recognized rare complication of epidural anesthesia and the incidence is not exactly well-known in thoracic epidural anesthesia. therefore, this study prospectively evaluates the incidence of horner's syndrome after thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy. six hundred thirty three patients, who scheduled for mastectomy with/without breast reconstruction, were eligible for this prospective observational study from september 2010 to december 2013. thoracic epidural anesthesia performed using 0.375% or 0.5% ropivacaine 15ml followed by sedation consisting of propofol without muscle relaxation. after the operation, thoracic epidural analgesia continued; supplemented by a continuous epidural infusion of ropivacaine 0.15%, 2 ml/h with fentanyl 8mcg/h. at 1 hour, 2hour, 1 day, 2 day and 3 day after the operation, postoperative surveillance consisted of the occurrence of symptoms of horner's syndrome (miosis, ptosis, and hyperemia) were performed by anesthesiologists.

Eligibility criteria:
inclusion criteria: * patients, who scheduled for mastectomy with/without breast reconstruction exclusion criteria: * the patients who had more than one abnormal preoperative clotting parameter either clinical signs of potential bleeding disorders suggested by bruising * petechiae, or ecchymosis, or anatomic or neurologic abnormalities * that is, significant scoliosis or kyphosis, radyculopathy or ptosis * unsuccessful catheter placement (impossible to insert a catheter at two vertebral levels) * unsuccessful epidural anesthesia (not checkable sensory block) * dural perforation or intravascular catheterization

Keywords: anesthesia epidural thoracic nerves horner syndrome
adhesion formation following laparoscopic and open colorectal surgery

Conditions: Adhesions

Summary: to ascertain whether there are fewer adhesions (internal scars) formed following laparoscopic (key-hole) surgery for colorectal diseases than traditional open surgery.


Eligibility criteria:
inclusion criteria: * previous elective colonic or rectal resection * having a further operative intervention at which time a laparoscopy can be performed exclusion criteria: * children \<18 * further surgery not relating to the primary colorectal surgery

Keywords: adhesions laparoscopy colorectal surgery colorectal disease
clinical comparative evaluation of the use of photodynamic therapy in conjunction with the use of vitamin d in management stage ii grade b periodontitis patients

Conditions: Vitamin D Deficiency

Summary: clinical comparative evaluation of the use of photodynamic therapy in conjunction with the use of vitamin d in management stage ii grade b periodontitis patients: a randomized controlled clinical trial.

this randomized clinical trial evaluates the effect of photodynamic therapy alone with srp versus photodynamic therapy with srp and vitamin d regarding clinical evaluation 1. clinical attachment loss (cal) 2. probing pocket depth (ppd) 3. bleeding on probing (bop)

Eligibility criteria:
inclusion criteria: * systemic healthy patients * patients aged \> 25 years * patients suffering from stage ii periodontitis with grade b were included in this study, according to 2017 world workshop classification of periodontal disease. * patients with interdental clinical attachment loss (cal) of 3-4 mm with radiographic evidence of bone loss extending to coronal third of the root. * radiographic bone loss (rbl) will be diagnosed using periapical parallel technique using 6 radiographic images for full mouth (3- radiographic images for maxillary arch and 3- radiographic images for mandibular arch) including anterior, canine region and posterior teeth at baseline for diagnosis. * no history of previous periodontal therapy. * no taken medications known to interfere healing or periodontal tissue health such as anticonvulsants, calcium channel blockers, or immunosuppressant drugs. * no previous periodontal surgery at involved sites. * good oral hygiene and good compliance with the plaque control instructions following initial therapy. * neither taken antibiotics within the last three months nor nonsteroidal anti-inflammatory drugs within the last three months * absence of diseases or conditions that would interfere with wound healing such as diabetes mellitus or coagulation disorders exclusion criteria: patients taking vitamin d as a nutritional supplement were excluded from the study * smoking habits * pregnant and lactating mothers * patients who have been received periodontal surgery in the study area during the last 6 months.
saif: sacroiliac fusion study

Conditions: Sacroiliac Joint Dysfunction

Summary: the purpose of the saif study is to evaluate the simmetry sacroiliac joint fusion system for fusion and pain reduction of the si joint.

this is a prospective, non-randomized, single center study to collect data on fusion and pain reduction following implantation of the simmetry device. up to 15 total subjects will be implanted and followed for 24 months. data will be collected pre-operatively, at implant, discharge, and at specified follow-up time points (6 weeks, 3 months, 6 months, 12 months, 24 months.)

Eligibility criteria:
inclusion criteria: * subjects must be indicated for the simmetry device according to the approved simmetry labeling * subject has three (3) positive (experiences pain) provocative tests for sij pain; for example, compression, thigh thrust, faber, distraction or gaenslen's * subject has documentation of failed, non-operative management of sij pain for ≥ 6 months prior to surgery; for example, use of medications, braces, si belts, orthotics, physical therapy or manual manipulation * the subject has one (1) positive diagnostic sij injection, resulting in a ≥50% decrease in pain from the anesthetic portion of the injection * the subject has vas back pain score of ≥ 60 mm * the subject has an odi ≥ 40% * the subject is at least 18 years of age and skeletally mature * the subject agrees and is able to comply with study requirements exclusion criteria: * subjects contraindicated per the cleared labeling will be excluded from participation in the study * the subject has pelvic soft tissue or bony tumors * the subject has had any trauma causing fracture of the sacrum or iliac bones or has had spinal trauma leading to a neurological deficit * the subject has a history of a central nervous system (cns) disorder(s) * the subject is pregnant or is planning on becoming pregnant in the next two years * the subject has chemical dependency problems as evidenced by a history of drug abuse which is documented in their past medical history or is elicited from an interview * the subject has a history of significant emotional or psychosocial disturbance (anxiety attacks, obsessive/compulsive disorders, depression or schizophrenia) as documented in their past medical history or elicited by an interview

Keywords: sacroiliac joint fusion sij fusion si joint